Related Experiment Videos
Insights
Growth hormone (GH) therapy is only approved for GH-deficient children. Using GH for other conditions is experimental and requires more research on efficacy and safety.
Area of Science:
- Pediatrics
- Endocrinology
- Medical Research
Background:
- Growth hormone (GH) replacement is an established therapy solely for GH-deficient children.
- The use of GH in non-GH-deficient children is considered experimental and lacks comprehensive data.
- Short stature can have psychological origins, necessitating careful patient selection for GH therapy.
Purpose of the Study:
- To highlight the need for controlled clinical trials evaluating GH therapy in specific non-GH-deficient populations.
- To emphasize the necessity of developing predictive methods for identifying responders among short, non-GH-deficient children.
- To underscore the importance of safety assessments for pharmacologic GH doses in non-GH-deficient children.
Main Methods:
- Review of current indications and experimental uses of GH therapy.
- Identification of research gaps in understanding GH efficacy and safety in non-GH-deficient populations.
- Discussion of patient selection criteria for investigational GH studies.
Main Results:
- GH therapy is definitively indicated only for GH deficiency.
- Significant need exists for rigorous clinical trials in conditions like constitutional growth delay, intrauterine growth retardation, and Turner syndrome.
- Safety and efficacy data for non-GH-deficient children are insufficient, warranting cautious use.
Conclusions:
- Indiscriminate use of GH in short, non-GH-deficient children is not advised until further controlled studies are completed.
- Investigational GH therapy should prioritize children with potential for significant emotional status improvement, balancing benefits against long-term treatment burdens.
- Physicians should carefully consider the established indications and potential psychological factors before initiating experimental GH treatment.
Abstract:
Replacement of GH in GH-deficient children is the only established indication for GH therapy. Treatment of all non-GH-deficient patients must be considered experimental. There is a pressing need for carefully controlled clinical trials of the effect of GH in patients with constitutional growth delay, intrauterine growth retardation, and Turner's syndrome. Research is needed to develop reliable methods for predicting which short, non-GH-deficient children will respond to GH therapy. GH is a potent metabolic agent, and its safety when used in pharmacologic doses for treatment of short, non-GH-deficient children has not been established. Until adequate experience is gained under controlled conditions, GH should not be used indiscriminately. As the investigational use of GH is expanded, researchers and clinicians should bear in mind that handicaps resulting from short stature often have psychological origins. Therefore, even for experimental studies, GH therapy should be restricted to children in whom it is judged that emotional status can be significantly improved. The potential for benefit should outweigh the problems of long-term parenteral therapy. In selecting patients for GH trials the wise physician might adhere to the old adage, "If it ain't broke, don't fix it."